Literature DB >> 1972629

Multidrug resistance and its circumvention.

W T Beck1.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 1972629     DOI： 10.1016/0277-5379(90)90028-r

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  8 in total

1.  P-glycoprotein structure and evolutionary homologies.

Authors:  I Bosch; J M Croop
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

2.  Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.

Authors:  Olga V Leontieva; Maria N Preobrazhenskaya; Ralph J Bernacki
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

Review 3.  P-glycoprotein structure and evolutionary homologies.

Authors:  J M Croop
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate.

Authors:  L Wang; C P Yang; S B Horwitz; P A Trail; A M Casazza
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Fluoxetine hydrochloride enhances in vitro susceptibility to chloroquine in resistant Plasmodium falciparum.

Authors:  L Gerena; G T Bass; D E Kyle; A M Oduola; W K Milhous; R K Martin
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

6.  Idarubicin is active on MDR cells: evaluation of DNA synthesis inhibition on P388 cell lines.

Authors:  M Petrini; L Mattii; P Valentini; A R Sabbatini; B Grassi; M Grandi
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

7.  Functional expression of P-glycoprotein encoded by the mouse mdr3 gene in yeast cells.

Authors:  S Ruetz; M Raymond; P Gros
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

8.  In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.

Authors:  M Ripamonti; G Pezzoni; E Pesenti; A Pastori; M Farao; A Bargiotti; A Suarato; F Spreafico; M Grandi
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.